Madrigal announces new clinical data demonstrating rezdiffra™ (resmetirom) significantly improved multiple noninvasive tests and portal hypertension risk in patients with compensated mash cirrhosis

Conshohocken, pa., may 10, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today announced positive two-year results from the open-label compensated mash cirrhosis (f4c) arm of the phase 3 maestro-nafld-1 trial of rezdiffra. patients (n=122) in the study achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (csph).
MDGL Ratings Summary
MDGL Quant Ranking